Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis

Vaccine

Volumn 21, Issue 25-26, 2003, Pages 3534-3541

  Pinto, Eduardo Fonseca ^a   De Mello Cortezia, Marcelle ^a   Rossi Bergmann, Bartira ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Leishmania; Oral vaccine; Tolerance

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; LEISHMANIA VACCINE; PARASITE ANTIGEN; PROTOZOAL VACCINE; T LYMPHOCYTE RECEPTOR;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; FEMALE; HYPERSENSITIVITY REACTION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INFECTION PREVENTION; INTESTINE MUCOSA; LEISHMANIA MAJOR; MESENTERY LYMPH NODE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; SKIN LEISHMANIASIS; TH1 CELL;

EID: 0242286027     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00427-4     Document Type: Article

References (37)

1. WHO/TDR. Tropical Diseases Research: Leishmaniasis. Fourteen Programme Report; 1999. p. 22.
2. Berman J.D. Chemotherapy for leishmaniasis: biochemical-mechanisms, clinical efficacy and future strategies. Rev. Infect. Dis. 10(3):1988;560-586.
3. Lira R., Sundar S., Makharia A.et al. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J. Infect. Dis. 180(2):1999;564-567.
4. Handman E. Leishmaniasis: current status of vaccine development. Clin. Microbiol. Rev. 14(2):2001;229-243.
5. Velez I.D., Agudelo S.D., Arbelaez M.P.et al. Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomised controlled trial. Trans. R. Soc. Trop. Med. Hyg. 94(6):2000;698-703.
6. Nascimento E., Mayrink W., Costa C.A.et al. Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses. Infect. Immun. 58(7):1990;2198-2203.
7. Liew F.Y., Hodson K., Lelchuk R. Prophylactic immunization against experimental leishmaniasis. VI. Comparison of protective and disease-promoting T cells. J. Immunol. 139(9):1987;3112-3117.
8. Liew F.Y., Hale C., Howard J.G. Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection. J. Immunol. 135(3):1985;2095-2101.
9. Kenney R.T., Sacks D.L., Sypek J.P., Vilela L., Gam A.A., Evans-Davis K. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J. Immunol. 163(8):1999;4481-4488.
10. Czerkinsky C., Anjuere F., McGhee J.R.et al. Mucosal immunity and tolerance: relevance to vaccine development. Immunol. Rev. 170:1999;197-222.
11. Julia V., Rassoulzadegan M., Glaichenhaus N. Resistance to Leishmania major induced by tolerance to a single antigen. Science. 274:1996;421-423.
12. McSorley S.J., Rask C., Pichot R., Julia V., Czerkinsky C., Glaichenhaus N. Selective tolerization of Th1-like cells after nasal administration of a cholera toxoid-LACK conjugate. Eur. J. Immunol. 28:1998;424-432.
13. Rossi-Bergmann B., Lenglet A., Bezerra-Santos C.R., Costa-Pinto D., Traub-Czeko Y.M. Use of fluorescent Leishmania for faster quantitation of parasite growth in vitro and in vivo. Mem. I Oswaldo Cruz. 94(Suppl II):1999;74.
14. Scott P., Afonso L.C. Immune responses associated with susceptibility of C57Bl/10 mice to Leishmania amazonensis. Infect. Immun. 61(7):1993;2952-2959.
15. Dhaliwal J.S., Liew F.Y. Induction of delayed-type hypersensitivity to Leishmania major and the concomitant acceleration of disease development in progressive murine cutaneous leishmaniasis. Infect. Immun. 55(3):1987;645-651.
16. Gorczynski R.M., Chen Z., Hoang Y., Rossi-Bergmann B. A subset of gamma delta T-cell receptor-positive cells produce T-helper type 2 cytokines and regulate mouse skin graft rejection following portal venous pretransplant preimmunization. Immunology. 87:1996;381-389.
17. Krause I., Blank M., Shoenfeld Y. Immunomodulation of experimental autoimmune diseases via oral tolerance. Critic. Rev. Immunol. 20(1):2000;1-16.
18. Bagot M., Terki N., Bacha S., Moyse D., Suck C., Revuz J. Per os desensitization for nickel contact hypersensitivity double-blind placebo-controlled clinico-biological study. Ann. Dermatol. Vener. 126(6/7):1999;502-504.
19. Winkler B., Baier K., Wagner S.et al. Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice. Clin. Exp. Allergy. 32(1):2002;30-36.
20. Sato M.N., Fusaro A.E., Oliveira V.C.R.et al. Oral tolerance induction in Dermatophagoides pteronyssinus: sensitized mice induces inhibition of IgE response and up regulation of TGF-beta secretion. J. Interf. Cytok. Res. 21(10):2001;827-833.
21. Howard J.G., Nicklin S., Hale C., Liew F.Y. Prophylactic immunization against experimental leishmaniasis. I. Protection induced in mice genetically vulnerable to fatal Leishmania tropica infection. J. Immunol. 129(5):1982;2206-2212.
22. Aebischer T., Morris L., Handman E. Intravenous infection of irradiated Leishmania major into susceptible BALB/c mice: immunization or protective tolerance. Int. Immunol. 6:1994;1535-1543.
23. Julia V., Glaichenhaus N. CD4 (+) T cells which react to the Leishmania major LACK antigen rapidly secrete interleukin-4 and are detrimental to the host in resistant B10-D2 mice. Infect. Immun. 67(7):1999;3641-3644.
24. Fujihashi K., Koga T., van Ginkel F.W., Hagiwara Y., McGhee J.R. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine. 20:2002;2431-2438.
25. Xu D., McSorley S.J., Chatfield S.N., Dougan G., Liew F.Y. Protection against Leishmania major infection in genetically susceptible BALB/c mice by GP63 delivered orally in attenuated Salmonella typhimurium AROA(-) AROD(-). Immunology. 85:1995;1-7.
26. Mowat A.M. The regulation of immune responses to dietary protein antigens. Immunol. Today. 8(3):1987;93-98.
27. Satoskar A., Okano M., David J.R. Gamma delta T cells are not essential for control of cutaneous Leishmania major infection in genetically resistant C57BL/6 mice. J. Infect. Dis. 176:1997;1649-1652.
28. Rosat J.P., MacDonald H.R., Louis J.A. A role for gamma-delta + T-cells during experimental infection of mice with Leishmania major. J. Immunol. 150:1993;550-555.
29. Strobel S., Mowat A.M., Drummond H.E., Pickering M.G., Ferguson A. Immunological responses to fed protein antigens in mice. II. Oral tolerance for CMI is due to activation of cyclophosphamide-sensitive cells by gut-processed antigen. Immunology. 49:1983;451-456.
30. Bruce M.G., Strobel S., Hanson D.G., Ferguson A. Transferable tolerance for cell-mediated immunity after feeding is prevented by radiation damage and restored by immune reconstitution. Clin. Exp. Immunol. 70:1987;611-618.
31. Haas W., Pereira P., Tonegawa S. Gamma-delta cells. Annu. Rev. Immunol. 11:1993;637-685.
32. Hayday A., Theodoridis E., Ramsburg E., Shires J. Intraepithelial lymphocytes: exploring the Third Way in immunology. Nat. Immunol. 2:2001;997-1003.
33. Hanninen A., Harrison L.C. Gamma delta T cells as mediators of mucosal tolerance: the autoimmune diabetes model. Immunol. Rev. 173:2000;109-119.
34. Czerkinsky C., Sun J.B., Holmgren J. Oral tolerance and anti-pathological vaccines. Curr. Top. Microbiol. 236:1999;79-91.
35. Titus R.G., Lima G.C., Engers H.D., Louis J.A. Exacerbation of murine cutaneous leishmaniasis by adoptive transfer of parasite-specific helper T cell populations capable of mediating Leishmania major specific delayed-type hypersensitivity. J. Immunol. 133:1984;1594-1600.
36. Tsuji N.M., Mizumachi K., Kurisaki J.I. Interleukin-10-secreting Peyer's patch cells are responsible for active suppression in low-dose oral tolerance. Immunology. 103(4):2001;458-464.
37. De Luca P.M., Mayrink W., Alves C.R.et al. Evaluation of the stability and immunogenicity of autoclaved and no autoclaved preparations of a vaccine against American tegumentary leishmaniasis. Vaccine. 17:1999;1179-1185.